Pharmaceutical drug
POPULARITY
7 episodes with lucentis
3 episodes with lucentis
6 episodes with lucentis
2 episodes with lucentis
2 episodes with lucentis
4 episodes with lucentis
2 episodes with lucentis
5 episodes with lucentis
3 episodes with lucentis
Wall Street closed Tuesday's session higher in yet another volatile session as traders took advantage of market uncertainty ahead of Trump's tariff handouts on April 2nd US time, and on the back of weaker-than-expected economic data weighing on investor sentiment. The S&P500 rose 0.38%, the Dow Jones added 0.03% and the Nasdaq ended the day up 0.87%. Investor sentiment was also hit by the Institute for Supply Management manufacturing survey coming in lighter than expected and in contraction territory for February, while February's job openings were also slightly below estimates in signs the economy is slowing due to tariff implications on US economic stability.In Europe overnight, markets reversed Monday's losses to close higher as eurozone inflation data for March showed inflation in the region cooled as expected to 2.2% for the month. The STOXX 600 rose 1.07%, Germany's DAX added 1.7%, the French CAC gained 1.1% and, in the UK, the FTSE100 ended the day up 0.61%.Across the Asia markets on Tuesday, markets also rebounded in the region following Monday's sell-off as investors await clarity on Trump's incoming tariffs, Japan's Nikkei rose 0.11%, South Korea's Kospi Index added 1.62%, Hong Kong's Hang Seng gained 0.38% and China's CSI index ended the day flat.The local market started the trading week mixed with the third-worst session of 2025 posted on Monday followed by a recovery on Tuesday with the key index ending Tuesday's session up 1%.The RBA also held the nation's cash rate at 4.1% for the next period to assess the unfolding trade situation with the US and to ensure inflation in Australia remains on track in the target range of 2-3%.Elsewhere in the economic data space, Australia's latest retail sales figures for February were released yesterday coming in at a rise of 0.2% for February which fell short of economists' expectations and is a positive reading for Australia's inflation journey easing as consumer spend is a big contributor to inflationary pressures.Investors really are riding the wave of volatility right now ahead of Trump's ‘Liberation Day' reciprocal tariff day in the US on Wednesday the 2nd April whereby it is expected the US President will announce an array of tariffs on countries that he believes have been unfairly taxing US imports for some time.The recent volatility has propelled gold to yet another record high overnight with the price of the commodity touching US$3145/ounce as investors flock to the safe-haven asset during times of high uncertainty.What to watch today:Ahead of the midweek trading session here in Australia the SPI futures are anticipating the ASX will open the day up 0.35% tracking Wall Street's rally overnight.On the commodities front this morning, oil is trading 0.33% lower at US$71.25/barrel, gold is down 0.24% at US$3112/ounce and iron ore is up 0.08% at US$102.51/tonne.The Aussie dollar has slightly strengthened against the greenback overnight to buy US$0.62, 93.70 Japanese Yen, 48.44 British pence and NZ$1.10 cents.Trading Ideas:Bell Potter has downgraded Opthea (ASX:OPT) to a sell rating from a buy rating and have dropped the 12-month price target on the company to 5cps following the release of Phase 3 trial results that failed to show any benefit in improving visual acuity when combined with either Eylea or Lucentis across both primary and key secondary endpoints.And Bell Potter has raised the 12-month price target on Aristocrat Leisure (ASX:ALL) from $83 to $85 and maintain a buy rating on the hotels and gaming company after the company's Phoenix Link has grown to 750 units in the EK database after just 4-months with performance strong at 2.5x floor average although trending down. The analyst expects operating momentum in FY25 to accelerate, particularly in Gaming Operations.
Dr. Carlos Quezada-Ruiz is a Vitreoretinal Surgeon and Assistant Professor of Ophthalmology at the Instituto de Oftalmologia Fundación Conde de Valenciana's Retina Department in Mexico City. He also serves as the Senior Vice President of Clinical Research and Development and Therapeutic Area Head (Ophthalmology) at 4DMT, leading early- and late-stage clinical development teams focused on treating neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and geographic atrophy (GA). In addition to his active clinical practice, Dr. Quezada-Ruiz has spent the past decade as a Drug Developer, beginning at Genentech–Roche. There, he worked on the Ophthalmology management team as Group Medical Director of Clinical Science (Product Development). During his tenure, he led the design, execution, and analysis of U.S. and global registrational trials for multiple retinal diseases, including the nAMD global clinical development program for VABYSMO, resulting in U.S. and worldwide approvals. He also led the global clinical science team for SUSVIMO, supporting its initial global filing, FDA approval, and launch in nAMD; successfully navigated the U.S. voluntary recall and commercial relaunch; and oversaw the phase 3 DR/DME registrational program through execution, readout, and filing with the FDA in early 2024. Previously, Dr. Quezada-Ruiz led Medical Affairs efforts for the U.S. launch of Lucentis Prefilled Syringe (PFS) and the myopic choroidal neovascularization indication for LUCENTIS. Furthermore, Dr. Quezada-Ruiz contributed to diversity and inclusion strategies in the Ophthalmology Franchise—such as the AAO MOM program—and advanced personalized healthcare in retina at Genentech by helping design and develop predictive models that use machine learning and large language models to support both drug development and clinical practice. Dr. Quezada-Ruiz is a Fellow of the American Society of Retina Specialists, with over 13 years of clinical practice and research in vitreoretinal diseases and surgery. He earned his M.D. from Universidad Autónoma de Coahuila in his hometown of Torreón, Mexico. He completed fellowships in Vitreoretinal Surgery, Ocular Pathology Research, and Vitreoretinal Surgery Research at Universidad Nacional Autónoma de México, McGill University, and the California Retina Research Foundation, respectively. In 2023, he completed an Executive Education program (CIBE) at Columbia Business School. His accolades include the 2023 Roche Award of Excellence in recognition of outstanding contributions to Roche Pharmaceuticals (“Vabysmo and Beyond”), Genentech's 2023 Medical Excellence Award, the 2019 American Society of Retina Specialists Senior Honor Award, the 2016 ASRS Honor Award, the 2013 Gillingham Pan-American Fellowship by the Pan-American Association of Ophthalmology and The Retina Research Foundation of Houston, Texas, and the 2013 Leonard Ellen Ocular Pathology Award by the Royal Victoria Hospital Foundation. On a personal note, Dr. Quezada-Ruiz is married to Cecy—formerly a marketing specialist at The Coca-Cola Company—and they have three children and a white Labrador, Mia, who is blind from retinal dystrophy. He is also a retired martial artist, philosopher, and health enthusiast. About 4DMT 4DMT is a clinical-stage genetic medicines company focused on harnessing the full potential of genetic therapies for large market diseases, particularly in ophthalmology (wet AMD and DME) and pulmonology (cystic fibrosis lung disease). Therapeutic Vector Evolution (TVE): 4DMT's proprietary vector platform leverages the Nobel Prize–winning technology of directed evolution to create customized viral vectors. This approach propels a diverse product pipeline aimed at revolutionizing medicine with potentially curative therapies for millions of patients.
El edema macular diabético es una complicación frecuente de la diabetes, en la que el daño a los vasos sanguíneos de la parte posterior del ojo provoca inflamación. Lucentis, Eylea y Avastin son tres fármacos antiangiogénicos que pueden inyectarse en el ojo para tratar estos vasos sanguíneos y reducir la inflamación y recientemente han aparecido fármacos con efectos más duraderos, como Vabysmo y Beovue. En junio de 2023 se actualizó una revisión Cochrane sobre estos medicamentos y se utilizó un metanálisis en red para comparar sus efectos. En este podcast se habla sobre sus hallazgos. Este podcast ha sido traducido por Yasmín García y locutado por Andrea Cervera del Centro Cochrane Iberoamericano.
El edema macular diabético es una complicación frecuente de la diabetes, en la que el daño a los vasos sanguíneos de la parte posterior del ojo provoca inflamación. Lucentis, Eylea y Avastin son tres fármacos antiangiogénicos que pueden inyectarse en el ojo para tratar estos vasos sanguíneos y reducir la inflamación y recientemente han aparecido fármacos con efectos más duraderos, como Vabysmo y Beovue. En junio de 2023 se actualizó una revisión Cochrane sobre estos medicamentos y se utilizó un metanálisis en red para comparar sus efectos. En este podcast se habla sobre sus hallazgos. Este podcast ha sido traducido por Yasmín García y locutado por Andrea Cervera del Centro Cochrane Iberoamericano.
Diabetic macular oedema is a common complication of diabetes, in which damage to the blood vessels at the back of the eye leads to swelling. Lucentis, Eylea and Avastin are three antiangiogenic drugs that can be injected into the eye to treat these blood vessels and reduce the swelling; and drugs with longer lasting effects have recently become available, such as Vabysmo and Beovue. In June 2023, Katie Curran from Queen's University Belfast in the UK and colleagues, updated their Cochrane review of these drugs and used a network meta-analysis to compare their effects. Here's Katie to tell us more.
Diabetic macular oedema is a common complication of diabetes, in which damage to the blood vessels at the back of the eye leads to swelling. Lucentis, Eylea and Avastin are three antiangiogenic drugs that can be injected into the eye to treat these blood vessels and reduce the swelling; and drugs with longer lasting effects have recently become available, such as Vabysmo and Beovue. In June 2023, Katie Curran from Queen's University Belfast in the UK and colleagues, updated their Cochrane review of these drugs and used a network meta-analysis to compare their effects. Here's Katie to tell us more.
Robert Avery, MD, CEO of California Retina Consultants, balances roles as physician and researcher with a lucrative additional career: advising life sciences companies and ophthalmology focused venture capital funds. With colleague and podcast host Firas Rahhal, MD, Dr. Avery talks about how he got into the business side of medicine. He also looks back over 30 years of retina, which includes pioneering the use of anti-VEGF agents for retinal disease.Looking forward, Dr. Avery shares his views on what's on the horizon for drug delivery platforms. And for the drug and device developers in the audience, he discusses how to leverage scientific advisory boards to gain valuable, practical insight.Listen to the podcast today to discover:How Dr. Avery built his clinical research practice in Santa Barbara, California. It's home to University of California Santa Barbara, a Tier 1 research university, but otherwise not a primary center for clinical trials.Tales from the early days of Avastin, including how Dr. Avery helped get the drug approved for off-label use to treat age-related macular degeneration. That it was approved for off-label use before Lucentis received FDA approval helped it become part of the standard of care.How Dr. Avery balances clinical practice with advisory roles and how these dual careers benefit one another.His prediction on emerging drug delivery platforms.What it takes to advise an investment group on drugs and devices as they relate to clinical practice. In other words, will doctors use this?Hit “Play” to Listen.
Ur innehållet: Nytt läkemedel likvärdigt med Lucentis godkänt i EU. Guldkassettens hederspris till Skånes Taltidning. Psykisk ohälsa viktig fråga för Månadens ansikte. Jordiga färger sticker ut i höstens dammode.
Phase 3 data evaluating the biosimilarity of a new biosimilar (Xlucane, Xbrane Biopharma) referencing ranibizumab (Lucentis, Genentech) has been completed. What were the results? Anat Loewenstein, MD, joined New Retina Radio to walk us through the results of the XPLORE study. And Ramanath Bhandari, MD, summarized his presentation on the TRUCKEE study, a real-world evaluation of the performance of faricimab (Vabysmo, Genentech/Roche). What do the most recent updates tell us about practice patterns and patient response?
Ram Palanki, PharmD, VP of commercial strategy and operations for REGENXBIO, has been involved in the development and launch of at least two groundbreaking treatments: Lucentis (ranibizumab, Genentech/Roche) and Macugen (pegaptanib).If all goes well in clinical trials, Dr. Palanki could soon add one more to his extensive CV: a one-time gene therapy designed to treat age-related macular degeneration and diabetic retinopathy (DR). A master of back-of-the-eye product development and commercialization, Dr. Palanki sits down with OIS podcast host Firas Rahhal, MD, to discuss the history of retinal disease treatments and the potential of gene therapy to address early- and later-stage disease.He hopes REGENXBIO's lead product, RGX-314, helps resolve the adherence issues that plague anti-VEGF drugs, the current standard of care. Currently in Phase III trials, RGX-314 introduces a trans gene that can encode for a therapeutic protein for life—a concept REGENXBIO is exploring for the first time. Clinical trials also show a potential benefit for DR. Interim data show about 50% of patients demonstrated a two-step or greater improvement in visual acuity from baseline at six months after a single dose. Listen to the podcast today to hear Dr. Palanki and Dr. Rahhal discuss: What it was like to be involved in the groundbreaking Lucentis and Macugen launches.How REGENXBIO plans to solve the sustainability problem that arose with the advent of anti-VEGF therapies.The history, mechanism of action, and route of administration behind RGX-314, REGENXBIO's lead program.The strength of RGX-314's adeno-associated viral vector (AAV) and other novel AAV vectors (NAV) technology platform.The philosophy behind REGENXBIO's DR program, including the potential of treating healthy eyes with RGX-314.How Dr. Palanki's responsibilities differ between development and commercialization. Click “play” to listen.
A neurostimulation device has been cleared for post-C-section pain; a new plaque psoriasis treatment; the FDA address the contrast agent shortage; Lucentis biosimilar treatment is approved; and the recall for an over-the-counter laxative is expanded.
Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest ophthalmic industry news and interview Allison W. Shuren, JD, MSN. Welcome to the Eyeluminaries podcast :10 A review of the previous episode :30 News and notes with John and Jim 1:20 On the return of in-person medical meetings 1:28 Byooviz, biosimilar to Lucentis, to be available July 1 2:40 First patient dosed in the phase 3 registrational COMET-2 study of AR-15512 for the treatment of dry eye disease signs and symptoms 5:50 Apellis Pharmaceuticals submitted a new drug application to the FDA for intravitreal pegcetacoplan, for the treatment of geographic atrophy secondary to age-related macular degeneration 9:04 Kala enters agreement to sell commercial portfolio to Alcon 11:30 FTC opens investigation into pharmacy benefit managers 13:30 Introduction of Allison W. Shuren, JD, MSN 15:45 The interview 17:44 The FTC investigation of pharmacy benefit managers and other enforcement trends 18:12 Have you seen an increase in cases against practices and industry and if so, why? 19:36 Prior authorization and trends in reduced access to care 22:12 What advice would you give to practices who are considering selling to private equity? 23:50 What advice are you giving to the private equity buyers? 25:32 What advice would you give to young surgeons coming out now to succeed in the future? 27:19 Introducing the next guest, David Chang, MD 30:55 Allison W. Shuren, JD, MSN, is a partner at the law firm Arnold & Porter, where she co-chairs the life sciences and healthcare regulatory practice and advises a wide range of health care clients on regulatory, compliance, enforcement and legislative matters. Before starting her career as a lawyer, she was a practicing critical care pediatric nurse practitioner. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. You can reach Shuren via email at allison.shuren@arnoldporter.com. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.
Scientist, entrepreneur, and executive Thomas Chalberg, PhD, has developed or funded companies that have advanced complex gene therapy technology, a novel anesthesia delivery system, and a lens that helps slow myopia progression in kids. And that's just the start.A leader in gene therapy development who is recognized by the World Economic Forum as a Technology Pioneer, Dr. Chalberg cofounded Avalanche Biotechnologies, which is now Adverum Biotechnologies. There, he built the Avalanche Ocular BioFactory, an adeno-associated virus (AAV)–based, proprietary, next-generation platform for the discovery and development of gene therapy vectors for ophthalmology.While much of his career has centered on gene therapy, one of his more recent ventures, SightGlass Vision, falls on the opposite end of the spectrum. The company has developed a novel spectacle lens design that helps slow myopia progression. Its foundation stems from research by the University of Washington, which found that high retinal contrast signaling leads to high myopia and that modifying that signaling could slow myopia progression.Dr. Chalberg also is founder and managing director of Polymerase Capital; founder and managing director of iRenix Medical, which developed a novel anesthesia delivery system used in conjunction with intravitreal injections; director of Chameleon Biosciences, a gene therapy–focused startup; and founder and CEO of Genascence Corp., a gene therapy startup developing products for musculoskeletal disease.In between all this activity, Dr. Chalberg caught up with Firas Rahhal, MD, to talk about—what else?—gene therapy, along with retinal disease and his history in the anti-VEGF market.Listen to the podcast today to hear: About Dr. Chalberg's work at Genentech during Lucentis' launch and early commercialization. The philosophy behind iRenix Medical's anesthesia delivery system, which administers a cooling anesthesia via an automated injector. His thoughts on the safety and effectiveness of gene therapy and gene editing for ophthalmic indications and how he sees it evolving over the next several years. Will it replace monoclonal antibodies, serve as an adjunct, or neither? How Dr. Chalberg got started in ophthalmology and retinal disease specifically.Click “play” to listen.
Jill Hopkins, MD, didn't plan to end up in a global leadership position at one of the world's largest pharmaceutical companies. But she got there in 2021, when Novartis recruited her to serve as its SVP and global head of the ophthalmology development unit. Dr. Hopkins moved from academia to the clinic to industry, not by muscling her way in, but by exploring opportunities that sparked her interest and fueled her passion. At each steppingstone, she had a hand in some exciting developments. At Novartis, she leads drug development for its mid- to late-stage portfolio, including both anterior- and posterior-segment therapeutics. She brings a depth of experience to the role that includes science, medicine, and academia, with stints at large companies and small startups.After 10 collective years at University or Toronto and University of Southern California, Dr. Hopkins moved to Retina Vitreous Associates. There, she worked alongside OIS Podcast host Firas Rahhal, MD, running the electroretinography lab and working on ciliary-derived neurotrophic factor clinical trials.Opportunities to join Genentech, UNITY Biotechnology, and then Roche followed, with each experience building on the other. At the latter, she was involved in the development of both Lucentis (ranibizumab) and Susvimo, the port delivery system with ranibizumab, before Novartis came calling. Listen to the podcast today to hear Dr. Hopkins and Dr. Rahhal discuss:How Dr. Hopkins' time in academia, the clinic, and industry allowed her to become a well-rounded professional.Her involvement in Susvimo from clinical trials through to commercial launch. What will endure among the numerous therapies and delivery systems in development for the posterior segment. How the industry can rise above the high bar set by current anti-VEGF therapies. How artificial intelligence can and will help clinicians define and measure outcomes.The outlook for regenerative medicine for the posterior segment. Click “play” to listen.
Der weltgrösste Pharmakonzern, im Besitz einer der reichsten Familien, geleitet vom bestbezahlten Manager der Schweiz: Roche ist ein Konstrukt der Superlative. Erstmals lassen sich die beiden Roche-Erben André Hoffmann und Jörg Duschmalé sowie Konzernchef Severin Schwan mit der Kamera begleiten. Roche hat sich mit seinen Türmen ein Denkmal gebaut. Mit 178 und 205 Metern sind sie die höchsten Gebäude der Schweiz und dominieren Basel – optisch wie sinnbildlich: Ohne Pharmakonzern würden wohl der grösste Steuerzahler und Tausende gut bezahlter Jobs fehlen. Und Basel könnte sich ohne das Mäzenatentum der Roche-Erben nicht Kulturhauptstadt nennen. Am Anfang, 1896, steht Fritz Hoffmann-La Roche. Seine Strategie: Medikamente industriell fertigen, diese mit viel Marketing verkaufen und schnell international expandieren. 125 Jahre später ist Roche nicht nur zum weltgrössten Pharmakonzern angewachsen, der Gigant ist auch noch immer im Besitz der Gründerfamilie. Ihre Mitglieder gehören zu den Reichsten der Schweiz, aber auch zu den Verschwiegensten. André Hoffmann, Ur-Enkel des Gründers, und sein Neffe 2. Grades Jörg Duschmalé lassen sich nun aber erstmals von der Kamera begleiten und äussern sich ausführlich über den Roche-Clan: Wie dieser Einfluss auf den Konzern nimmt und mit WhatsApp untereinander kommuniziert, warum die Erben die Medien meiden und was sie mit ihren Milliarden machen, die sie dank der seit 34 Jahren stetig steigenden Roche-Dividende erhalten. André Hoffmanns grösstes Anliegen ist die Nachhaltigkeit. Er ist geprägt von seinem Vater Luc, der den WWF mitgegründet hat. Nachhaltiges Handeln fordert André Hoffmann als Verwaltungsrat darum auch von Roche – eine schwierige Vorgabe für einen Weltkonzern, der seine riesigen Gewinne teilweise auch mit strafbaren Methoden erzielt hat, wie der Fall des Vitamin-Kartells zeigt. Aktuell hängig ist etwa der Fall der Medikamente Avastin und Lucentis zur Behandlung von Altersblindheit, wo vorinstanzlich bereits hohe Millionen-Bussen ausgesprochen wurden. Jörg Duschmalé ist erst seit eineinhalb Jahren Verwaltungsrat. Zuvor hat der 37-jährige promovierte Chemiker bei Roche geforscht. Eine prägende Zeit, wie der Besuch mit ihm im Labor bei einem ehemaligen Arbeitskollegen zeigt. Heute konzentriert sich Jörg Duschmalé aber auf das Mandat als Verwaltungsrat. Als solcher beaufsichtigt er Konzernchef Severin Schwan. Dieser muss für die Erben-Familie den Erfolg langfristig sichern und gleichzeitig als CEO eines börsenkotierten Unternehmens jedes Quartal die Erwartungen der Anleger erfüllen. Zu Hilfe kommt ihm derzeit das Geschäft mit der Pandemie, zu deren Bekämpfung Roche Corona-Tests und PCR-Geräte liefert. Darum wird Severin Schwan – zur eigenen Überraschung – auch direkt auf seinem Handy von Regierungschefs um Auskunft gebeten. Der Film von Tobias Bossard zeigt eindrücklich, wie das System Roche mit den Erben im Hintergrund funktioniert, und gibt so einen exklusiven Einblick in den weltgrössten Pharmakonzern.
Der weltgrösste Pharmakonzern, im Besitz einer der reichsten Familien, geleitet vom bestbezahlten Manager der Schweiz: Roche ist ein Konstrukt der Superlative. Erstmals lassen sich die beiden Roche-Erben André Hoffmann und Jörg Duschmalé sowie Konzernchef Severin Schwan mit der Kamera begleiten. Roche hat sich mit seinen Türmen ein Denkmal gebaut. Mit 178 und 205 Metern sind sie die höchsten Gebäude der Schweiz und dominieren Basel – optisch wie sinnbildlich: Ohne Pharmakonzern würden wohl der grösste Steuerzahler und Tausende gut bezahlter Jobs fehlen. Und Basel könnte sich ohne das Mäzenatentum der Roche-Erben nicht Kulturhauptstadt nennen. Am Anfang, 1896, steht Fritz Hoffmann-La Roche. Seine Strategie: Medikamente industriell fertigen, diese mit viel Marketing verkaufen und schnell international expandieren. 125 Jahre später ist Roche nicht nur zum weltgrössten Pharmakonzern angewachsen, der Gigant ist auch noch immer im Besitz der Gründerfamilie. Ihre Mitglieder gehören zu den Reichsten der Schweiz, aber auch zu den Verschwiegensten. André Hoffmann, Ur-Enkel des Gründers, und sein Neffe 2. Grades Jörg Duschmalé lassen sich nun aber erstmals von der Kamera begleiten und äussern sich ausführlich über den Roche-Clan: Wie dieser Einfluss auf den Konzern nimmt und mit WhatsApp untereinander kommuniziert, warum die Erben die Medien meiden und was sie mit ihren Milliarden machen, die sie dank der seit 34 Jahren stetig steigenden Roche-Dividende erhalten. André Hoffmanns grösstes Anliegen ist die Nachhaltigkeit. Er ist geprägt von seinem Vater Luc, der den WWF mitgegründet hat. Nachhaltiges Handeln fordert André Hoffmann als Verwaltungsrat darum auch von Roche – eine schwierige Vorgabe für einen Weltkonzern, der seine riesigen Gewinne teilweise auch mit strafbaren Methoden erzielt hat, wie der Fall des Vitamin-Kartells zeigt. Aktuell hängig ist etwa der Fall der Medikamente Avastin und Lucentis zur Behandlung von Altersblindheit, wo vorinstanzlich bereits hohe Millionen-Bussen ausgesprochen wurden. Jörg Duschmalé ist erst seit eineinhalb Jahren Verwaltungsrat. Zuvor hat der 37-jährige promovierte Chemiker bei Roche geforscht. Eine prägende Zeit, wie der Besuch mit ihm im Labor bei einem ehemaligen Arbeitskollegen zeigt. Heute konzentriert sich Jörg Duschmalé aber auf das Mandat als Verwaltungsrat. Als solcher beaufsichtigt er Konzernchef Severin Schwan. Dieser muss für die Erben-Familie den Erfolg langfristig sichern und gleichzeitig als CEO eines börsenkotierten Unternehmens jedes Quartal die Erwartungen der Anleger erfüllen. Zu Hilfe kommt ihm derzeit das Geschäft mit der Pandemie, zu deren Bekämpfung Roche Corona-Tests und PCR-Geräte liefert. Darum wird Severin Schwan – zur eigenen Überraschung – auch direkt auf seinem Handy von Regierungschefs um Auskunft gebeten. Der Film von Tobias Bossard zeigt eindrücklich, wie das System Roche mit den Erben im Hintergrund funktioniert, und gibt so einen exklusiven Einblick in den weltgrössten Pharmakonzern.
REGENXBIO ($RGNX) presents data using the Clearside Bio ($CLSD) SCS injector to treat wet AMD and diabetic retinopathy patients with RGX-314. Since existing treatments are on the market for these indications, it is very important that safety signals in these studies are reduced to a minimum. It is also critical that efficacy remains non-inferior to Eylea or Lucentis. In this video, I go through both readouts and discuss the potential for the therapy moving forward. 4D Molecular Therapeutics ($FDMT) announces positive early interim data in their intravitreal treatment of 4D-125 in patients with X-linked Retinitis Pigmentosa. With only a small patient population to analyze, it is difficult to derive much conclusion, but so far the efficacy and safety is hopeful. Patients advanced in their disease and also had an extensive prophylactic regimen, making it difficult to assess the treatment's success. In this video, I go through the details of the space and talk about what's next for FDMT. Help out the show (or join the discord) by becoming a patron at: https://www.patreon.com/breakingbiotech Follow me on twitter @matthewlepoire Send me an email matthewlepoire@gmail.com www.breakingbiotech.com #breakingbiotech Disclaimer: All opinions expressed by Matt (or his guests) in this podcast are solely his (their) opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech
We may be on the cusp of the next great era of wet AMD therapy. Which phase 3 data will guide physician decision-making if new technologies are approved by regulatory bodies? Chirag Jhaveri, MD, spoke with New Retina Radio about anatomic data collected in the phase 3 ARCHWAY study. How did patients who received the Port Delivery System with Ranibizumab (PDS, Genentech) differ from those on monthly ranibizumab (Lucentis, Genentech) in terms of fluctuation in central subfield thickness? And as FDA weighs the possible approval of faricimab for the treatment of wet AMD, we hear from Karl Csaky, MD, PhD, about the safety, efficacy, and durability of the drug for wet AMD in the TENAYA and LUCERNE studies.
This podcast is about big ideas on how technology is making life better for people with vision loss. Today's big idea is: How will remote diagnostic tests change ophthalmology and vision care? It might be a foreign concept for some, but the specialists in today's episode, Dr. Peter Pham and Dr. Sean Ianchulev, founders of (Keep Your Sight, a nonprofit focused on remote diagnostic vision tests) share how they can conduct more reliable perimetry tests that help detect macular degeneration, glaucoma, and other conditions that lead to vision loss and eventually blindness — remotely, while patients stay home. Developments like these in remote diagnostics are a stepping stone for the ways machine learning will impact the field of ophthalmology in the future. This episode also features Dr. Einar Stefansson and Dr. Arna Gudmundsdottir, developers of the app, Retina Risk, which helps with remote risk assessment of diabetic eye disease for people with diabetes, as well as Sherrill Jones, who lost her vision due to glaucoma. The Big Takeaways: Retina Risk was created to help people with diabetes assess in real-time their individualized risk for sight-threatening diabetic retinopathy. The app was created back in 2009 and the concept of using technology and algorithms to calculate risk was still quite foreign to most people. What goes into taking a regular perimetry test today? Patients have to come into the office, wait, register, wait some more, get taken to a dark room to be positioned correctly, and after 20-30 minutes, you get a result. Now, there's an easier way: patients can take these tests at home. Why is telescreening so important? Dr. Pham and Dr. Ianchulev noticed it could take months for patients to be scheduled in for routine visual field tests. By that time, the glaucoma may have advanced, and in some cases, rapidly. There was an unmet need here and there was a better way to serve people quicker and more efficiently, especially people from rural communities who did not have readily available access to healthcare. Medicare did not allow for doctors to reimburse their services unless it was conducted within the physician's office. This led to a lot of roadblocks in telemedicine, despite the technology being available for the last 15-plus years. Thankfully, in December of 2020, policies were changed so that doctors would be reimbursed for remote patient monitoring. Tweetables: “We know that our blindspot is 15 degrees away from fixation and, with simple trigonometry, you can now use that blindspot to help position patients correctly in front of the computer monitor. We can now use online technology to perform visual field tests.” — Dr. Peter Pham “It was our goal to do a hardware-free digital/virtual device. We felt in ophthalmology, we're kind of lucky. We are looking at a visual function. So perimetry lends itself to a fully virtual software as a service device.” — Dr. Sean Ianchulev “I think technology will help us get to the next level. Technology has been around for this, but it hasn't been applied for this.” — Dr. Sean Ianchulev Contact Us: Contact us at podcasts@lighthouseguild.org with your innovative new technology ideas for people with vision loss. Pertinent Links: Lighthouse Guild Retina Risk Keep Your Sight.org Guest Bios: Dr. Peter Pham & Dr. Sean Ianchulev are both the Co-Founders of Keep Your Sight. Dr. Pham is a boarded certified ophthalmologist who has devoted his professional life to restoring sight and helping patients keep their vision. As a surgeon and clinician, Dr. Pham treats conditions such as glaucoma, cataract, and macular degeneration, all of which can cause blindness. As a researcher, he worked on the development of a novel delivery system for introducing large-sized molecular compounds into thousands of living cells simultaneously. Realizing the importance of technology and innovation for screening and prevention, Dr. Pham teamed up with Dr. Ianchulev to develop the KYS telemedicine system for vision health. Dr. Ianchulev has been on the cutting edge of innovation, making an impact in the treatment of major eye diseases such as macular degeneration and glaucoma. He was instrumental in the development of many new therapies and advances, such as Lucentis for AMD and Diabetic Retinopathy, intraoperative aberrometry for high-precision cataract surgery, micro-stent technology for glaucoma, the miLOOP interventional technology for cataract surgery, and others. Dr. Einar Stefansson & Dr. Arna Gudmundsdottir are both the Co-Founders of Retina Risk. Dr. Stefansson is a leader in the field of diabetic eye disease and diabetic screening and head supervisor for product development and clinical science. Dr. Stefansson graduated from the University of Iceland Medical School in 1978 with honors. He received a PhD degree in physiology from Duke University in 1981 followed by a residency at Duke. Dr. Gudmundsdottir takes an active role in all product development and clinical testing. Her expertise gives valuable insight into practical usage of products and medical approaches. Dr. Gudmundsdottir graduated from the University of Iceland Medical School in '92. She undertook a fellowship program in endocrinology at the University of Iowa Hospital and Clinics. Sherrill Jones lives in New York City and volunteers administrative services in Lighthouse Guild's Volunteer Services department. Host Bio: Dr. Calvin W. Roberts Calvin W. Roberts, MD, is President and Chief Executive Officer of Lighthouse Guild, the leading organization dedicated to providing exceptional services that inspire people who are visually impaired to attain their goals. Dr. Roberts has a unique blend of academic, clinical, business, and hands-on product development experience. Dr. Roberts is a Clinical Professor of Ophthalmology at Weill Cornell Medical College. He was formerly Senior Vice President and Chief Medical Officer, Eye Care, at Bausch Health Companies where he coordinated global development and research efforts across their vision care, pharmaceutical, and surgical business units. As a practicing ophthalmologist from 1982 to 2008, he performed more than 10,000 cataract surgeries as well as 5,000 refractive and other corneal surgeries. He is credited with developing surgical therapies, over-the-counter products for vision care, prescription ocular therapeutics, and innovative treatment regimens. He also holds patents on the wide-field specular microscope and has done extensive research on ophthalmic non-steroidals and postoperative cystoid macular edema. Dr. Roberts has co-founded a specialty pharmaceutical company and is a frequent industry lecturer and author. He currently serves as an Independent Director on multiple corporate boards and has served as a consultant to Allergan, Johnson & Johnson, and Novartis. A graduate of Princeton University and the College of Physicians and Surgeons of Columbia University, Dr. Roberts completed his internship and ophthalmology residency at New York-Presbyterian Hospital/Columbia University Medical Center in New York. He also completed cornea fellowships at Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute in Boston.
In today's episode, we talk about diabetic retinopathy and cataracts. I dig into what causes this and how to mitigate the effects of such a disease. Enjoy the show! If you want more, sign up for my newsletter at: www.drsamberne.com. SUMMARY KEYWORDS retina, cataracts, eye, vitreous, msm, diabetic retinopathy, blood vessels, health, retinal, inflammation, neuroprotective, lens, body, tiny blood vessels, work, call, suggest, acid xanthine, taurine, eyedrops Hello, everyone, it's Dr. Sam, I'd like to welcome you to my EyeClarity podcast. This is a show that offers cutting-edge information on how to improve your vision and overall wellness through holistic methods. I so appreciate you spending part of your day with me. If you have questions, you can send them to hello@drsamberene.com. Now to the latest EyeClarity episode. 00:02 Hey everybody, its Dr. Sam and I'd like to welcome you to another EyeClarity podcast. I'm going to take a question today but before I do that I want to make an announcement for my upcoming course on improving lens health. So anybody that's concerned that they're developing cataracts they've been diagnosed with cataracts are thinking about cataract surgery. This is a class for you. So this is a two-week extravaganza, and it starts September 11. And it will run for two weeks, you will get a lot of information on how to improve your lens health like one piece of advice I would give to anybody who's suffering cataracts is eliminate sugar from your diet. research studies have shown that if you are having difficulties with managing your glucose levels, if you eat foods that have refined carbohydrates, or sugars, you run a higher risk of developing cataracts. Let's say that you are having difficulties with dietary absorption and you suffer inflammation in your gut. This actually can start to affect your eye health, especially the lens of the eye. So a cataract is basically metabolic waste that starts to accumulate in the a vascular structure we call the lens Why is it a vascular? Because there are no blood vessels that run directly to the lens of the eye. So what this does, this sets up a situation especially as we age that you lose the ability to as we say, Get rid of the trash in the recycling bin and it builds up and this is the oxidative stress that creates a cataract. So I highly recommend this course this for everybody. If you want to prevent cataracts and keep your lenses clear and healthy. You can sign up on my website drsamberne.com on my Instagram bio, on Facebook, a lot of ways to get in touch with me. You can also email me at hello@drsamberne.com. Yeah, and if you have to miss any of the classes, they will be video and audio recorded and you will have access to them. 60 days after the last class you also will receive 10% off on all my products on my webstore so check it out. Alright, today I want to take a question from Kara. And she is writing me from Instagram. Now it's interesting because in this this gal she is suffering diabetic retinopathy and cataracts. So the retinopathy part of it, of course, is in the retina. And diabetes really attacks the retina. She says that she's having bleeds in both eyes, and they've made her way to the vitreous, which is kind of the posterior two-thirds of the iPad sits in front of the retina. And she's been getting injections for the bleeding. Avastin is one and Lucentis is the other. These are common pharmaceutical drugs that are used, especially in wet macular degeneration, but any kind of retinopathy. These are the pharmaceutical drugs that are used that can slow down the degradation of the blood vessels. So she's really feeling compromised, and she's been on the ketogenic diet for a few years. But only recently has she gotten her blood sugar in control. And she's guessing that the damages from previous years have poor poor blood sugar, and mitochondria health. And so she's asking about supplementation.
Dr. Jeffrey Cleland, Ph.D., Chairman, CEO and President of Ashvattha Therapeutics, a clinical stage biotech company discusses treatments that are in development to address inflammation of the brain caused by COVID. They recently announced positive interim results on its ongoing phase 2 PRANA clinical study, which showed that OP-101, a novel hydroxyl dendrimer therapeutic, has the ability to successfully cross the blood brain barrier and suppress hyperinflammation. The company is also developing a class of novel hydroxyl dendrimer therapeutics that they hope will become the future of targeted therapies and unlock new levels of patient care across oncology, ophthalmology, and inflammatory diseases. #AshvatthaTherapeutics Dr. Cleland has 30 years of industry experience in research and development, including more than a decade at Genentech, Inc. His experience in startups includes major roles in obtaining more than $450 million in capital at stages from Series A through D and exit via IPO including over $300 million in capital raised as CEO. As the founding CEO of Versartis (VSAR), he led one of top biotech IPOs of all time. After Versartis, he led the Series B financing and clinical translation of novel Johns Hopkins University technology as CEO of Graybug Vision (GRAY). He held executive management positions at BaroFold, Novacea and Targesome, and has managed directly all aspects of drug development and late-stage research. While at Genentech, Dr. Cleland served in product development and manufacturing roles. He held important leadership roles in the successful approval of two drugs, Herceptin® and Nutropin Depot®, as well as in early work on Lucentis®, Avastin®, and Kadcyla®. He holds a BS in Chemical Engineering from the University of California, Davis and a PhD in Chemical Engineering from the Massachusetts Institute of Technology. Dr. Cleland has authored more than 100 articles and four books, and holds several issued patents. He serves on the Boards of BIO, Exicure, and Zylem and has advisory roles with small emerging biotechnology companies.
Dr. Jeffrey Nau, CEO of Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company discusses the company's lead candidate, OC-01, a nasal spray being developed to treat the signs and symptoms of dry eye disease (DED). Current treatment options are limited to eye drops, which can be difficult and uncomfortable to self-administer. The FDA accepted their New Drug Application for OC-01, which was supported by safety and efficacy results from clinical trials in over 1,000 patients with mild, moderate, or severe symptoms of DED. The U.S. launch of OC-01 nasal spray is planned for the fourth quarter of 2021, if approved by the FDA. Jeffrey Nau, PhD, MMS, President and Chief Executive Officer. Jeff has built his career on developing novel, innovative therapies for diseases of the eye, with over 15 years of experience working with biotechnology, pharmaceutical, and medical device companies. Most recently, he was VP, Clinical and Medical Affairs, at Ophthotech. Prior to that, Jeff was a Medical Science Director at Genentech working on the development of Lucentis®, a transformative drug for retinal diseases. Jeff has helped raise more than $250 million in equity for innovative startups such as Genaera Corporation, Acuity Pharmaceuticals, and NeoVista, Inc. He holds numerous patents and peer-reviewed publications. Jeff has a Ph.D. in Public Health and Epidemiology from Walden University, a M.S. in Medical Science from MCP Hahnemann School of Medicine, and a B.S. in Biology from Stony Brook University.
Robert Bhisitkul and Tejal Desai describe how treatment for retinal diseases leading to vision loss, such as age related macular degeneration, may be much improved by efforts to develop implantable devices for drug delivery. Age related macular degeneration (AMD) is one of several retinal diseases that can lead to vision loss and, ultimately, blindness. Dr. Bhisitkul explains that the class of anti-VEGF biologic drugs (Lucentis, Avastin, Eylea) can treat AMD, however, ongoing, monthly injections into the eye are required for the drugs to be fully effective. There are a number of drawbacks to this treatment regime, many of which could be mitigated by the development of a drug delivery device for implantation in the eye. Dr. Desai describes the work done in her lab to develop an injectable, biocompatible and biodegradable device that has the right release kinetics to successfully deliver needed drugs to the retina of patients with AMD.
BEH PODCAST EPISODE 50 - 8 Things Your Doctor is Not Telling You About Your Eye Disease, Part 2 of 8. Hint: Your Vision Can Improve. Welcome to the Organic MD podcast with Dr. Damon Miller. I am Carlyle Coash. We are continuing our discussion about health, wellness, and the things we can do to improve all of these in ourselves. We are going to be talking about what we can do to maintain your health. If there was ever a time to be attending to it, that time is now. Today we will begin talking about our Better Eye Health Program, which will be a total of eight podcasts. We work with people who have serious eye or retinal diseases, like macular degeneration, Stargardt’s disease, and retinitis pigmentosa. Our program has shown to be highly effective for helping people with these diseases. 8 Things Your Doctor is Not Telling You About Your Eye Disease, Part 2 of 8. Hint: Your Vision Can Improve. 050_OMDPodcast_8Things_MedicalHex-2of8Carlyle Welcome to the Organic MD podcast with Dr. Damon Miller. I am Carlyle Coash. We are continuing our discussion about health, wellness and the things we can do to improve all of these in ourselves. How are you today, Dr. Miller?Dr. Miller Hi Carlyle, I am actually pretty good today. We are still in a crazy time in the world, but it is good to be here. We are going to be talking about what we can do to maintain your health. If there was ever a time to be attending to it, that time is now. Today we will begin talking about our Better Eye Health Program, which will be a total of eight podcasts. We work with people who have serious eye or retinal diseases, like macular degeneration, Stargardt’s disease, and retinitis pigmentosa. Our program has shown to be very effective for helping people with these diseases.I want to start by honoring Grace Halloran, PhD. She was a pathfinder of this field and put the ideas of this program together. When people are diagnosed with these eye diseases, their stories are pretty consistent. They go to their doctor because they have trouble with their vision. They may have a family history of the disease and their vision is now starting to be affected. The doctor says they have a very serious eye disease, the problem cannot be helped with a new pair of glasses, and there is nothing they have to offer. If a doctor is not open-minded, they will probably say there is nothing that can be done. This is far from true, there is something you can do. We call this medical hexing, when a doctor tells someone there is nothing that will help. People respect their doctors; if they are told nothing can be done, they believe nothing can be done. If they were being honest, they would say there is no drug or surgery they know of. They would recommend taking some vitamins to slow down the progress, but mention no improvement will be seen in their visions over the course of their life. We work with people to improve their vision all the time and we are here to keep all hope alive. We will let you know what you need to do to salvage your vision, keep it from getting worse, and regenerate some of the vision lost. Today we will go over the basic understanding that the things you hear about and are offered by modern medicine do not treat the diseases, they are treat the complications of the diseases. The disease with the worst complications is macular degeneration and everyone who has this disease starts with dry macular degeneration. As the degeneration process continues, the retina eventually reaches a point where the structure and vessels break down; this leads to leaking and bleeding in the retina. We now have wet macular degeneration, formally exudative macular degeneration. Doctors have developed some interesting treatments that try to stop the bleeding and leaking because it can be very destructive. Drugs, like Avastin and Lucentis, are injected directly into your eye with a needle. It does stop the bleeding, but it does not treat the underlying problem.
Natural Eye Care with Dr. Marc Grossman, Holistic Optometrist
Angiogenesis is the unwanted growth of blood vessels in the retina that leads to vision loss. These excess blood vessels can obscure or distort vision, which damages the eye and may result in permanent damage. Eye doctors may give you injections of Eylea or Lucentis to inhibit the growth of these blood vessels, but some may want a more natural approach. Macular degeneration and diabetic retinopathy are prevalent in seniors over the age of 60. Wet macular degeneration, which is worse than dry macular degeneration, affects 10-15% of macular degeneration patients. Those with wet macular degeneration can lose their vision quickly if not taking precautions. Diabetic retinopathy affects about half of diabetic patients, in which new, fragile capillaries form in your eyes, distort your vision, and may even leak. Studies from Canadian and American researchers suggested that taking natural, herbal antioxidant supplements can halt the growth of these blood vessels. Researchers compiled a list of herbs that inhibit vascular endothelial growth factor, which is a signal protein cells make that tell the body to make new blood vessels. We recommend taking the Blood Vessel Control support formula that can be found on our website naturaleyecare.com
Retina specialist, Dr. Dominic Buzzacco, joins Dr. Suh to talk about age-related macular degeneration (AMD), one of the most common causes of central vision loss in people over 50. People with early AMD will notice distortion, blurred vision, a blind spot, or, sometimes, nothing.Risk factors include:Age over age 50CaucasianSmokingFamily history (a first-degree relative increases the risk seven-fold)Light-colored irisesUncontrolled cardiovascular disease and high blood pressureDry (non-exudative) AMD is by far the most common type and may be associated with retinal pigmentary abnormalities and soft drusen, yellow deposits found under the retina. About 10% of dry AMD patients will progress to the wet form.Wet (exudative or neovascular) AMD is characterized by the formation of abnormal blood vessels underneath the retina. These vessels may leak or bleed and cause scar tissue. Vision loss is more rapid with untreated wet AMD vs. the dry form.All patients with AMD should monitor their vision in each eye individually on a regular basis by using an Amsler grid.Patients with dry AMD should take AREDS 2 (Age-Related Eye Disease Study 2) vitamins to help slow down the progression of vision loss. Early diagnosis is important so that patients can be advised to start these eye vitamins. Patients who smoke should consider stopping.Those with wet AMD will probably need to have intraocular injections of so-called anti-VEGF medications to slow down or stop the abnormal vessel growth. The injections may contain the medications Avastin (bevacizumab), Lucentis (ranibizumab), Eylea (aflibercept), or Beovu (brolucizumab). These injections are not a cure but can keep the leaking or bleeding under control. Most patients will need monthly injections until all fluid / bleeding is absorbed and there is no evidence of recurrence. Some may need injections every eight to twelve weeks indefinitely. These medications have been a huge leap forward to stabilizing the disease in 95% of people and improving vision in 30-40% of eyes.Some risks of the injections include a subconjunctival hemorrhage (bruise) which goes away in a few days; temporary foreign body sensation; corneal abrasion; and intraocular infection (1:4000-5000 injections).Most patients will never go completely blind from their AMD even if central vision deteriorates because their peripheral vision remains intact.Some future treatments include a surgically implantable port (or reservoir) delivery system for injecting Lucentis. Gene therapy is also being studied to turn off the growth factors for abnormal blood vessels.Unfortunately, some AMD patients may lose enough of their useful vision to perform daily activities. Low vision aids can help those with permanent vision loss. Services are available to assess the types of devices that patients may need to help them function better.Here are some more resources on macular degeneration.Article #1Article #2To find out more about Dr. Buzzacco and his practice, go to Midwest Retina’s website.This is intended for informational and educational purposes only, and nothing in this podcast/blog is to be considered as recommending or rendering medical advice or treatment to a specific patient. Please consult your eye care specialist for proper diagnosis and treatment of any eye conditions that you may have.
Macular degeneration is a leading cause of vision loss in Australia 60 years of age and older. Advanced age-related macular degeneration is a leading cause of irreversible blindness and visual impairment in the world. However, not many people have heard about this condition. Nhan and Ishaan explain in deep about this preventable medication condition.If you like this episode, be sure to subscribe and leave us a review on iTunes!!https://podcasts.apple.com/au/podcast/breaking-the-capsule/id1479407995Follow us on Facebook and Instagram:https://www.facebook.com/Breaking-the-Capsule-110257606996674/https://www.instagram.com/breakthecap/?hl=enEmail us at contact@breakingthecapsule.com with any questions
Dr. Anne Fung is the Global Development Lead for the Port Delivery System with Ranibizumab and Lucentis at Genentech. She is also a practicing retina specialist and researcher at Pacific Eye Associates and California Pacific Medical Center in San Francisco. Macular degeneration is a degenerative condition of a portion of the retina in the eye. This disease generally affects older adults. While there are some amazing medicines that can help people with macular degeneration, these medicines must be injected into the eye every 4-6 weeks. Anne is working on a tiny implant that serves as a reservoir for medicine so it can be slowly released over 6 months or more. They are currently investigating how long this implant can effectively treat the disease. Outside of science, Anne loves practicing yoga, as well as reading, listening to podcasts, and listening to audiobooks on a variety of topics including business, organizations, and psychology. Anne received her undergraduate degree from Wellesley College and her Medical Degree from Cornell University. She completed her residency in ophthalmology at Stanford University School of Medicine and then pursued a Medical Retina Fellowship at the Bascom Palmer Eye Institute and the University of Miami Miller School of Medicine. Anne worked in clinical practice for ten years before joining the team at Genentech in 2014. Anne is a Board Certified Ophthalmologist and is a Fellow of the American Academy of Ophthalmology. In our interview she shares more about her life and science.
Dijabetički makularni edem je uobičajena komplikacija dijabetesa u kojoj oštećenje krvnih žila na stražnjem dijelu oka dovodi do oticanja. Lucentis, Eylea i Avastin su tri antiangiogena lijeka koji se mogu ubrizgati u oko kako bi se krvne žile izliječile, a oticanje smanjilo. Gianni Virgili sa Sveučilišta u Firenci u Italiji je u lipnju 2017. g. zajedno s kolegama ažurirao Cochraneov sustavni pregled tih lijekova i koristio mrežnu meta-analizu kako bi usporedio svoje učinke. Njegov osvrt nam je prevela Nina Raguž, suradnica hrvatskog Cochranea, a Irena Zakarija-Grković iz Hrvatskog Cochranea s Medicinskog fakulteta u Splitu će nam ga pročitati.
Dijabetički makularni edem je uobičajena komplikacija dijabetesa u kojoj oštećenje krvnih žila na stražnjem dijelu oka dovodi do oticanja. Lucentis, Eylea i Avastin su tri antiangiogena lijeka koji se mogu ubrizgati u oko kako bi se krvne žile izliječile, a oticanje smanjilo. Gianni Virgili sa Sveučilišta u Firenci u Italiji je u lipnju 2017. g. zajedno s kolegama ažurirao Cochraneov sustavni pregled tih lijekova i koristio mrežnu meta-analizu kako bi usporedio svoje učinke. Njegov osvrt nam je prevela Nina Raguž, suradnica hrvatskog Cochranea, a Irena Zakarija-Grković iz Hrvatskog Cochranea s Medicinskog fakulteta u Splitu će nam ga pročitati.
Dijabetički makularni edem je uobičajena komplikacija dijabetesa u kojoj oštećenje krvnih žila na stražnjem dijelu oka dovodi do oticanja. Lucentis, Eylea i Avastin su tri antiangiogena lijeka koji se mogu ubrizgati u oko kako bi se krvne žile izliječile, a oticanje smanjilo. Gianni Virgili sa Sveučilišta u Firenci u Italiji je u lipnju 2017. g. zajedno s kolegama ažurirao Cochraneov sustavni pregled tih lijekova i koristio mrežnu meta-analizu kako bi usporedio svoje učinke. Njegov osvrt nam je prevela Nina Raguž, suradnica hrvatskog Cochranea, a Irena Zakarija-Grković iz Hrvatskog Cochranea s Medicinskog fakulteta u Splitu će nam ga pročitati.
This episode answers questions related to pathological myopia, neovascularization, dry eyes, optic neuritis, glaucoma and epiretinal membrane. Question 1 0:00 - 12:52 My 15-year-old daughter has had pathological myopia since before 5 years of age. She's been wearing corrective lenses and recently was diagnosed with neovascularization. She had her first Lucentis injection, and her eye cleared up leaving a small scar. My husband and I want a holistic approach for our Angelina to aid as a preventive and overall eye health solution rather than have her get shots for damage already done. We appreciate any advice or suggestions for us to be able to preserve Angelina's eyesight. I've been giving her Omega 3 foods like Salmon, nuts, and cod liver oil, citrus fruits, and leafy green vegetables. Thank you. Question 2 12:52 - 21:01 I would like to order some supplements and need suggestions on what might be helpful. I am 67, and the blue headlights are hurting my eyes at night. I also have dry eye syndrome, and my eyes are tired. Can you tell me about photobiomodulation as a treatment modality? I try to do use this modality every night now for sleep. What do you think I should be doing? Question 3 21:01 - 26:30 Hi, Dr. Berne! Your site is great! Thank you for all of the educational info that you provide. I was wondering if you could do a blog post or a video about Optic Neuritis? I was diagnosed with this in my left eye a couple of years ago. I lost partial vision in that eye. I've not been able to find any information about what the root cause could be. I had an autoimmunity test done to make sure that I do not have M.S. and I don't... it was negative. The doctor called it "idiopathic" which seems ridiculous. I want to be proactive to prevent this from progressing further and from occurring in the other eye. Do you have thoughts about what else someone with Optic Neuritis should be tested for? Heavy metals, parasites, viruses, etc.? I certainly appreciate your help! Cheers. Question 4 26:30 - 29:39 Hi, I am 58 years old. I have been diagnosed with glaucoma. I suffer anxiety, and I am receiving some mental health counseling. What can you offer me? Question 5 29:40 - 37:01 I have recently been diagnosed with epiretinal membrane pseudo-hole. What supplements would be good for that? I'm considering some kind of drops, and I would also like a supplement with Lutein in it. Also, I am wondering about the best eye exercises. I am using the Amsler grid chart every day to monitor the macula. Thanks for any help you can offer!
This episode answers questions related to pathological myopia, neovascularization, dry eyes, optic neuritis, glaucoma and epiretinal membrane. Question 1 0:00 - 12:52 My 15-year-old daughter has had pathological myopia since before 5 years of age. She's been wearing corrective lenses and recently was diagnosed with neovascularization. She had her first Lucentis injection, and her eye cleared up leaving a small scar. My husband and I want a holistic approach for our Angelina to aid as a preventive and overall eye health solution rather than have her get shots for damage already done. We appreciate any advice or suggestions for us to be able to preserve Angelina's eyesight. I've been giving her Omega 3 foods like Salmon, nuts, and cod liver oil, citrus fruits, and leafy green vegetables. Thank you. Question 2 12:52 - 21:01 I would like to order some supplements and need suggestions on what might be helpful. I am 67, and the blue headlights are hurting my eyes at night. I also have dry eye syndrome, and my eyes are tired. Can you tell me about photobiomodulation as a treatment modality? I try to do use this modality every night now for sleep. What do you think I should be doing? Question 3 21:01 - 26:30 Hi, Dr. Berne! Your site is great! Thank you for all of the educational info that you provide. I was wondering if you could do a blog post or a video about Optic Neuritis? I was diagnosed with this in my left eye a couple of years ago. I lost partial vision in that eye. I've not been able to find any information about what the root cause could be. I had an autoimmunity test done to make sure that I do not have M.S. and I don't... it was negative. The doctor called it "idiopathic" which seems ridiculous. I want to be proactive to prevent this from progressing further and from occurring in the other eye. Do you have thoughts about what else someone with Optic Neuritis should be tested for? Heavy metals, parasites, viruses, etc.? I certainly appreciate your help! Cheers. Question 4 26:30 - 29:39 Hi, I am 58 years old. I have been diagnosed with glaucoma. I suffer anxiety, and I am receiving some mental health counseling. What can you offer me? Question 5 29:40 - 37:01 I have recently been diagnosed with epiretinal membrane pseudo-hole. What supplements would be good for that? I'm considering some kind of drops, and I would also like a supplement with Lutein in it. Also, I am wondering about the best eye exercises. I am using the Amsler grid chart every day to monitor the macula. Thanks for any help you can offer!
El edema macular diabético es una complicación habitual de la diabetes, en la cual las lesiones de los vasos sanguíneos detrás del ojo dan lugar a una hinchazón. Lucentis, Eylea y Avastin son tres fármacos antiangiogénicos que pueden inyectarse en el ojo para tratar estos vasos sanguíneos y reducir la hinchazón. En junio de 2017, Gianni Virgili de la Universidad de Florencia en Italia, y sus compañeros, actualizaron la revisión Cochrane sobre estos fármacos y utilizaron un metanálisis para comparar sus efectos.Este podcast ha sido traducido y grabado por Andrea Cervera del Centro Cochrane Iberoamericano.Nota: la última versión de esta revisión se publicó en octubre de 2018, pero las conclusiones que se describen en este podcast no han cambiado.
El edema macular diabético es una complicación habitual de la diabetes, en la cual las lesiones de los vasos sanguíneos detrás del ojo dan lugar a una hinchazón. Lucentis, Eylea y Avastin son tres fármacos antiangiogénicos que pueden inyectarse en el ojo para tratar estos vasos sanguíneos y reducir la hinchazón. En junio de 2017, Gianni Virgili de la Universidad de Florencia en Italia, y sus compañeros, actualizaron la revisión Cochrane sobre estos fármacos y utilizaron un metanálisis para comparar sus efectos.Este podcast ha sido traducido y grabado por Andrea Cervera del Centro Cochrane Iberoamericano.Nota: la última versión de esta revisión se publicó en octubre de 2018, pero las conclusiones que se describen en este podcast no han cambiado.
El edema macular diabético es una complicación habitual de la diabetes, en la cual las lesiones de los vasos sanguíneos detrás del ojo dan lugar a una hinchazón. Lucentis, Eylea y Avastin son tres fármacos antiangiogénicos que pueden inyectarse en el ojo para tratar estos vasos sanguíneos y reducir la hinchazón. En junio de 2017, Gianni Virgili de la Universidad de Florencia en Italia, y sus compañeros, actualizaron la revisión Cochrane sobre estos fármacos y utilizaron un metanálisis para comparar sus efectos.Este podcast ha sido traducido y grabado por Andrea Cervera del Centro Cochrane Iberoamericano.Nota: la última versión de esta revisión se publicó en octubre de 2018, pero las conclusiones que se describen en este podcast no han cambiado.
Charles Semba, MD, is one of the more recognized and accomplished figures in development of new ophthalmology treatments. He has played integral roles in the development of Lucentis, Xiidra, and more recently Forsight IV’s drug delivery technology. Now the chief medical officer at Graybug Vision, Dr. Semba is working to develop a technology that could significantly reduce the number of injections needed to deliver drugs to the back and front of the eye. But how did Dr. Semba, who had been a world renowned vascular specialist, run out such a string of successes in ophthalmology? And what is the biggest regret of his accomplished career?
Australia-based Opthea is moving forward with clinical trials in the US, testing its OPT-302 compound along and in combination with Lucentis as a potential treatment for Wet AMD. CEO Megan Baldwin explains the company’s approach up until now and its plans going forward.
Mark Porter visits a very smelly laboratory to find out how your gut bacteria could be influencing your weight - and more besides. Doctors have written to the authorities asking for permission to use the drug Avastin instead of the more expensive alternative, Lucentis, to treat patients with age related macular degeneration (AMD) - the commonest cause of blindness in older people. Inside Health investigates. And new research into peanut allergy, turning conventional wisdom on its head, that every parent should know.
Today in FirstWord:
Today in FirstWord:
Medizinische Fakultät - Digitale Hochschulschriften der LMU - Teil 17/19
Retinale venöse Gefäßverschlüsse (RVV) sind eine der Hauptursachen für einen Visusverlust in den westlichen Industriestaaten. Venenastverschlüsse (VAV) treten häufiger als Zentralvenenverschlüsse (ZVV) auf. Bei beiden Typen ist das Makulaödem der entscheidende Parameter für die funktionelle Einbuße. Zusätzliche Ischämien und Neovaskularisationen, gerade bei ZVV, führen am gesamten Auge zu teils schwerwiegenden Komplikationen, deren es, neben der Makulaödem-behandlung, vorzubeugen gilt. Mittlerweile sind Lucentis® als Anti-VEGF-Inhibitor sowie Ozurdex® als Steroid-Implantat (Dexamethason) zur Behandlung des Makulaödems bei venösen Gefäßverschlüssen zugelassen und stellen in der Therapie von RVV neben der konventionellen Laserbehandlung eine wesentliche Hauptsäule dar. Die vorliegende Arbeit untersucht den Vergleich der intravitrealen Therapie mit Dexamethason-Implantat (Ozurdex®, Gruppe 1) und Anti-VEGF-Injektion (Lucentis®, Gruppe 2) zur Behandlung des Makulaödems bei retinalen venösen Gefäßverschlüssen in einer retrospektiven, nicht randomisierten Fallserie. Gruppe 1 enthielt 60 Patienten (31 mit ZVV und 29 mit VAV) und Gruppe 2 inkludierte 52 Patienten (27 mit ZVV und 25 mit VAV). Im Falle eines Rezidivs wurden beide Gruppen jeweils weiter behandelt. Präoperativ und monatlich wurden die bestkorrigierte Sehschärfe (BKSS) und der intraokulare Druck (IOD) bestimmt, die zentrale Netzhautdicke mittels Spectralis-OCT erhoben, sowie eine Biomikroskopie und Fundusfotodokumentation durchgeführt. Primärer klinischer Endpunkt war die Visusentwicklung 12 Monate nach der ersten intravitrealen Therapie, sekundäre Endpunkte waren die zentrale Netzhautdicke und die Sicherheit der Therapie. Nach 12 Monaten wurde in der Gruppe 1 bei den ZVV-Patienten ein Anstieg der BKSS (± eine Standardabweichung) von 8,4 (± 1,9) Buchstaben, bei den VAV- Patienten ein Gewinn von 10,7 (± 3,8) Buchstaben beobachtet. In Gruppe 2 zeigten die ZVV-Patienten eine Zunahme der BKSS von 6,9 (± 1,9) Buchstaben nach 12 Monaten im Vergleich zu 12,5 (± 3,7) Buchstaben bei den VAV-Patienten. In beiden Gruppen konnte eine signifikante Reduktion der zentralen Netzhautdicke erreicht werden. Der IOD zeigte in knapp der Hälfte aller Fälle in Gruppe 1 einen Anstieg über 5 mmHg, konnte aber durch konservative antiglaukomatöse Therapie in den Fällen mit einem IOD über 21 mmHg (obere Normgrenze) in der Behandlungsphase gut reguliert werden. Allerdings zeigte sich bereits nach zweimaliger Ozurdex®-Injektion (Gruppe 1) in ca. 50% der Fälle eine Progression einer Linsentrübung. Eine Behandlung mit Ozurdex® führt bei den ZVV im Vergleich zu Lucentis® zu einem besseren Sehschärfenanstieg nach 12 Monaten, allerdings nicht signifikant. Bei den VAV ist der Sehschärfengewinn bei beiden Behandlungsformen ähnlich. Unabhängig von den Ergebnissen muss für Ozurdex® der Linsenstatus und das Alter des Patienten berücksichtigt werden.
Today in FirstWord:
As Global Head of Development Franchise Ophthalmics at Novartis, Dirk Sauer has overseen the development of Novartis’ blockbuster Lucentis. Now, his focus is on the pharmaceutical gi-ant’s pipeline of retina compounds, including many in the early stages. Hear how Sauer views innovation, both inside and outside of Novartis.
Today in FirstWord:
Today in FirstWord:
-Occhi, ipovisione: Rimborso terapia ranibizumab (Lucentis*) per Edema maculare diabetico, Occlusione venosa retinica, Degenerazione maculare neovascolare legata all'età la principale paura delle persone con diabete è la cecità. E' quanto emerge da un'indagine condotta su 2.407 pazienti, il 41% teme la cecità e il 34% le complicanze oculari. Il diabete, se non controllato, nel lungo periodo può provocare danni specifici alla retina, mettendo a rischio la funzionalità visiva e determinando una patologia invalidante come l'edema maculare diabetico, una complicanza della retinopatia diabetica, patologia cronica e progressiva a carico dei piccoli vasi retinici che rappresenta nei Paesi industrializzati la principale causa di cecità in età lavorativa. Oggi i pazienti affetti da diminuzione visiva causata da edema maculare diabetico possono avvalersi della terapia con ranibizumab (Lucentis®) che ha recentemente ottenuto la rimborsabilità a carico del Servizio Sanitario Nazionale anche per questa patologia. (Gazzetta Ufficiale n. 285 del 6 dicembre 2012). Ranibizumab è ad oggi l'unico farmaco anti-VEGF (fattore di crescita vascolare endoteliale) approvato per tre indicazioni terapeutiche: degenerazione maculare neovascolare legata all'età (wet-AMD), diminuzione visiva causata da edema maculare diabetico (DME) e da occlusione venosa retinica (RVO). Ha inoltre ricevuto recentemente l'estensione del rimborso a carico del SSN anche nei pazienti con wet-AMD e acuità visiva
Today in FirstWord:
Diabetes damages the blood vessels and if untreated, can lead to blindness. The newest discoveries with anti-VEGF therapy in diabetes have their own requirements. One question is when should a macular edema be treated and when not? So far, a clinically significant macular edema was the main criterion for therapy. There has been a shift from clinically significant macular edema towards the concept of "center involving or central subfiled thickening". With OCT, the course over time can now be controlled much more accurately. View video strategies in diabetes GETOCT 4 Youtube channel: The question is, which concept is better: "clinically significant macular edema" versus "center involving". In the label (package leaflet) of Lucentis is nothing written about retinal thickness. The single most important criterion is the visual acuity loss due to macular edema in diabetes. Monthly injections of Lucentis for three consecutive months until visual acuity is stable. Re-treatment, if the visual acuity is worse again. It is to discuss whether the visual acuity alone is a good parameter for treatment. What is a "clinically significant macular edema"? A GETOCT memory aid: important are two circles and a line (cross section papilla): 1. First inner circle with 500 microns around foveola 2. Second circle with one disc diameter around the the foveola 3. A line represents the disc diameter The definition of clinically significant macular edema is important: 1.Retinal thickening within 500 microns of the center (foveola) 2.Hard exudates within 500 microns around the foveola with adjacent retinal thickening 3. Retinal thickening greater than one disc diameter in order to one disc area around foveola The disadvantage of this arrangement is that the findings are not always clear. Diabetes is a vascular disease Diabetes affects vessels. Therefore, the assessment of the ischemic component is very important. Diabetes on the retina leads to a thinning of the peri foveolar capillary network. The normal fovelar avascular zone (FAZ) increases in size. Almost always, the lesions are irreversible. The capillary network is so badly damaged that swelling can not longer be caused, no edema is visible in advanced cases. In an avascular retina, OCT of the foveola shows completely thinner layers. The normal fine retinal layers are destroyed, but a few crumbs are visible. In very far-advanced stage, anti-VEGF and laser have no great benefit anymore for the visual acuity. The goal of therapy in very advanced situations is no longer the visual acuity, but to prevent vascular proliferations, thus bleeding and a secondary glaucoma or even blindness. Download video: Strategies in Diabetes GETOCT 4
Host Neil Bressler, MD, interviews Jennifer Lim, MD, and Judy Kim, MD. Dr. Neil Bressler leads a discussion on the management of patients with age-related macular degeneration. The participants consider a range of issues, including their approach to antibiotic use, the real-world implication of the published CATT outcomes, and the challenge of motivating patients who may be discouraged by a long-term regimen of intravitreal injections. (November 2011)
A conversation between Judy Kim, MD, and Neil M. Bressler, MD. Dr. Neil Bressler, chair of the Diabetic Retinopathy Clinical Research Network (DRCR.net), discusses this year
Host Neil Bressler, MD, interviews Carl Baker, MD, and Michael Elman, MD. Conversation includes the use of OCT and angiography in evaluating for potential treatment of DME. Participants share their insight on which patients and situations are appropriate for focal grid laser, anti-VEGF drugs, intravitreal triamcinolone, or some combination based on several complicating factors and recent studies. (November 2010)
Host Neil Bressler, MD, interviews Julia Haller, MD, Michael Ip, MD, and Andrew Schachat, MD. Conversation includes retinal vein occlusion in the scope of other diseases particular to the aging adult, how diagnosis is best established for a central retinal vein occlusion, and how to evaluate a patient over a course of long-term care. Also discussed is the use of anti-VEGF agents and intraocular steroids for the treatment of patients with macular edema related to vein occlusion. (November 2010)
Tue, 1 Jan 2008 12:00:00 +0100 http://bjo.bmj.com/content/92/9/1298.short https://epub.ub.uni-muenchen.de/14973/1/How_to_treat_recurrences_after_avastin.pdf Haritoglou, Christos; Kampik, Anselm; Strauss, R.; Kook, Daniel; Wolf, Armin
Guest: Philip J. Rosenfeld, M.D., Ph.D.Professor of OphthalmologyBascom Palmer Eye InstituteUniversity of Miami Miller School of MedicineMiami, Florida
© 2020-2025 Ivy Podcast Discovery LLC
